An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Top Cited Papers
- 30 September 2015
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 5 (10), 1049-1057
- https://doi.org/10.1158/2159-8290.cd-15-0443
Abstract
Oncogenic TRK fusions induce cancer cell proliferation and engage critical cancer-related downstream signaling pathways. These TRK fusions occur rarely, but in a diverse spectrum of tumor histologies. LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. Preclinical models of LOXO-101 using TRK-fusion–bearing human-derived cancer cell lines demonstrate inhibition of the fusion oncoprotein and cellular proliferation in vitro, and tumor growth in vivo. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the lung was found to harbor an LMNA–NTRK1 gene fusion encoding a functional LMNA–TRKA fusion oncoprotein as determined by an in situ proximity ligation assay. In a phase I study of LOXO-101 (ClinicalTrials.gov no. NCT02122913), this patient's tumors underwent rapid and substantial tumor regression, with an accompanying improvement in pulmonary dyspnea, oxygen saturation, and plasma tumor markers. Significance: TRK fusions have been deemed putative oncogenic drivers, but their clinical significance remained unclear. A patient with a metastatic soft-tissue sarcoma with an LMNA–NTRK1 fusion had rapid and substantial tumor regression with a novel, highly selective TRK inhibitor, LOXO-101, providing the first clinical evidence of benefit from inhibiting TRK fusions. Cancer Discov; 5(10); 1049–57. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 1005Keywords
Other Versions
This publication has 32 references indexed in Scilit:
- Oncogenic FGFR3 gene fusions in bladder cancerHuman Molecular Genetics, 2012
- The transcriptional landscape and mutational profile of lung adenocarcinomaGenome Research, 2012
- Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resectionJournal of the European Academy of Dermatology and Venereology, 2011
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic TumorNew England Journal of Medicine, 2010
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomasEuropean Journal Of Cancer, 2009
- Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyJournal of Clinical Oncology, 2007
- Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard CareThe Oncologist, 2005
- Nerve Growth Factor-Induced Migration of Endothelial CellsJournal of Pharmacology and Experimental Therapeutics, 2005
- Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responsesNeuron, 1994
- Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGFNature, 1991